Bicycle Therapeutics plc
BCYC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35,275 | $26,976 | $14,463 | $11,697 |
| % Growth | 30.8% | 86.5% | 23.6% | – |
| Cost of Goods Sold | $172,966 | $156,496 | $0 | $0 |
| Gross Profit | -$137,691 | -$129,520 | $14,463 | $11,697 |
| % Margin | -390.3% | -480.1% | 100% | 100% |
| R&D Expenses | $172,966 | $156,496 | $81,609 | $44,880 |
| G&A Expenses | $71,462 | $59,832 | $49,507 | $32,435 |
| SG&A Expenses | $71,462 | $59,832 | $49,507 | $32,435 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$172,247 | -$155,902 | $0 | $0 |
| Operating Expenses | $72,181 | $60,426 | $131,116 | $77,315 |
| Operating Income | -$209,872 | -$189,946 | -$116,653 | -$65,618 |
| % Margin | -595% | -704.1% | -806.6% | -561% |
| Other Income/Exp. Net | $36,076 | $10,739 | $2,412 | -$2,864 |
| Pre-Tax Income | -$173,796 | -$179,207 | -$114,241 | -$68,482 |
| Tax Expense | -$4,765 | $1,457 | -$1,524 | -$1,663 |
| Net Income | -$169,031 | -$180,664 | -$112,717 | -$66,819 |
| % Margin | -479.2% | -669.7% | -779.3% | -571.2% |
| EPS | -2.91 | -5.08 | -3.8 | -2.67 |
| % Growth | 42.7% | -33.7% | -42.3% | – |
| EPS Diluted | -2.9 | -5.08 | -3.8 | -2.67 |
| Weighted Avg Shares Out | 58,208 | 35,592 | 29,661 | 25,062 |
| Weighted Avg Shares Out Dil | 58,208 | 35,592 | 29,661 | 25,062 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34,284 | $14,002 | $5,756 | $120 |
| Interest Expense | $1,730 | $3,263 | $3,344 | $2,984 |
| Depreciation & Amortization | $7,177 | $6,546 | $3,689 | $1,409 |
| EBITDA | -$164,892 | -$183,400 | -$107,208 | -$64,089 |
| % Margin | -467.4% | -679.9% | -741.3% | -547.9% |